This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Apricus Biosciences To Present Review Of Commercialization Plans For Vitaros(R) And Development Of Product Pipeline At BioPartnering North America Conference(TM)

Stocks in this article: APRI

SAN DIEGO, Calif., Feb. 10, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), ( http://www.apricusbio.com ) today announced that Linda Smibert, Vice President, Business Development at the Company's NexMed, USA, Inc. ("NexMed, USA") subsidiary, will present at the BioPartnering North America Conference in Vancouver, Canada, on Tuesday, March 1, 2011, at 10:15 am PST. The presentation will include an overview of the Company's commercialization plans for Vitaros ®, its first approved product, as well as development of the Company's 12 other products and compounds utilizing its proprietary NexACT ® technology. 

On November 12, 2010, Apricus Bio announced that Health Canada had approved Vitaros ® for marketing as the first topical treatment for ED in that country. The Company announced on December 22, 2010 a licensing agreement with Bracco SpA for the commercialization of Vitaros ® in Italy, and on January 4, 2011, announced the signing of a licensing agreement with Elis Pharmaceuticals for the Gulf Countries and certain countries in the Middle East. Apricus Bio is currently in proactive discussions to expand the commercialization of Vitaros ® to certain other international markets.

Commenting on the upcoming presentation, Dr. Bassam Damaj, President and Chief Executive Officer of the Company, noted, "We are very excited to have this opportunity to present a review of our commercialization progress for Vitaros ® at such a key industry event. Our business development group at NexMed USA has been very proactive in seeking appropriate licensing and commercialization partners throughout the world in order to potentially make this promising drug available to patients in many different countries. In addition to this review, Ms. Smibert will be presenting an update on our 12 other products and compounds in development, including later stage products, such as MycoVa for onychomycosis (nail fungus), PrevOnco for liver cancer, Femprox ® for female sexual arousal disorder, and RayVa for Raynauld's Syndrome, as well as our pre-clinical products in development, in the areas of sexual dysfunction, oncology, autoimmune disease, anti-inflammatory, pain, anti-infectives, diabetes and cosmeceuticals. We are enthusiastic about the opportunity to discuss these products, as well as the underlying NexACT ® technology, and how it may help other companies achieve better results from their own compounds and products."

About Apricus Biosciences, Inc.

Apricus Bio, a San Diego based revenue-generating pharmaceutical company,  has leveraged the flexibility of its clinically-validated NexACT ® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide, as well as monetizing its existing product pipeline, including its approved drug, Vitaros ®, for treatment of erectile dysfunction, in addition to compounds in development from pre-clinical through Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals, among others.  For further information on Apricus Bio and its subsidiaries, visit http://www.apricusbio.com

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, timing for seeking foreign approvals for Vitaros ®, timing and success of the commercial launch of Vitaros ® in Italy, The Gulf Countries and part of the Middle East and in Israel and the Palestinian Territories, the potential size of the markets in each of these countries, the ability to develop and commercialize the Company's products on its own and with partners and the ability to meet its milestones. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

CONTACT:  Apricus Biosciences, Inc.
          Edward Cox
          VP, Investor Relations & Corporate Development
          (858) 848-4249
          ecox@apricusbio.com
         
          Apricus Bio Investor Relations
          Paula Schwartz
          Rx Communications Group, LLC
          (917) 322-2216
          pschwartz@rxir.com

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,828.24 +0.49 0.00%
S&P 500 2,067.56 -5.27 -0.25%
NASDAQ 4,791.63 +4.3130 0.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs